AU Patent

AU2024287308A1 — Rna-editing oligonucleotides and uses thereof

Assigned to Korro Bio Inc · Expires 2025-12-18 · 0y expired

What this patent protects

The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an RNA produces a therapeutic result in a subject in need thereof.

USPTO Abstract

The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an RNA produces a therapeutic result in a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024287308A1
Jurisdiction
AU
Classification
—
Expires
2025-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Korro Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.